Onfasprodil

Onfasprodil (MIJ821) is a drug delivered via intravenous infusion that is designed as a fast-acting treatment for treatment-resistant depression. It works as a negative allosteric modulator of the NMDA receptor subunit 2B (NR2B). The drug is developed by Novartis.^[1][2]

Onfasprodil

Clinical data
Other names	MIJ821
Drug class	NMDA receptor modulator
Legal status
Legal status	Investigational
Identifiers
IUPAC name 6-{(1S)-2-[(3aR,5R,6aS)-5-(2-Fluorophenoxy)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1-hydroxyethyl}-3-pyridinol
CAS Number	1892581-29-1
PubChem CID	118981713
ChemSpider	115010425
UNII	C6I8M5AWKP
KEGG	D12787
ChEMBL	ChEMBL5095074
Chemical and physical data
Formula	C20H23FN2O3
Molar mass	358.413 g·mol−1
3D model (JSmol)	Interactive image
SMILES O([C@@H]1C[C@@]2([C@](C1)(CN(C[C@H](O)C3=CC=C(O)C=N3)C2)[H])[H])C4=C(F)C=CC=C4
InChI InChI=1S/C20H23FN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,19,24-25H,7-8,10-12H2/t13-,14+,16+,19-/m0/s1 Key:NEFQLCKWVRZEJA-ZDXGLAPJSA-N